Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1207293 | 0.87 | CA14 (0.39) | CA14KCNQ4KCNQ5HDAC1HDAC2 | |
| SCHEMBL1688918 | 0.86 | CA14 (0.35) | CA14KCNQ4KCNQ5HDAC1HDAC2 | |
| SCHEMBL20029121 | 0.85 | CA14 (0.34) | CA14KCNQ4KCNQ5HDAC1HDAC2 | |
| SCHEMBL3174629 | 0.83 | CA14 (0.36) | CA14KCNQ4KCNQ5HDAC1HDAC2 | |
| SCHEMBL18829734 | 0.83 | CA14 (0.36) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL78691 | 0.83 | CA14 (0.41) | CA14HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL3530471 | 0.82 | CA14 (0.36) | CA14KCNQ4KCNQ5HDAC1HDAC2 | |
| SCHEMBL7421637 | 0.81 | CTSK (0.35) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL3177412 | 0.81 | KCNQ4 (0.36) | CA14KCNQ4KCNQ5HDAC1HDAC2 | |
| SCHEMBL15481109 | 0.80 | CA14 (0.33) | CA14HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | claimed |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-02-03 | — | — | US | claimed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | claimed |
| US-11974975-B2 | Compositions and methods using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+ precursor | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-05-07 | — | — | US | claimed |
| US-20240100006-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-03-28 | — | — | US | claimed |
| US-20240091186-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-03-21 | — | — | US | claimed |
| EP-4262776-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2023-10-25 | — | — | EP | claimed |
| US-11730711-B2 | Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels | BAYLOR COLLEGE OF MEDICINE (US) | 2023-08-22 | — | — | US | claimed |
| US-20230172232-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2023-06-08 | — | — | US | claimed |
| WO-2022128870-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2022-06-23 | — | — | WO | claimed |
| US-20210244696-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | BAYLOR COLLEGE OF MEDICINE | 2021-08-12 | — | — | US | claimed |
| EP-3855943-A2 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | Société des Produits Nestlé S.A. (CH) | 2021-08-04 | — | — | EP | claimed |
| CN-112654264-A | Using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+Composition and method of precursors | 雀巢产品有限公司 | 2021-04-13 | — | — | CN | claimed |
| US-10952982-B2 | Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2021-03-23 | — | — | US | claimed |
| CN-112028916-A | Programmed cell death protein receptor-1 targeted molecular probe and preparation | 江苏省原子医学研究所 | 2020-12-04 | — | — | CN | claimed |
| WO-2020064946-A2 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | Société des Produits Nestlé S.A. (CH) | 2020-04-02 | — | — | WO | claimed |
| US-20180161297-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | Société des Produits Nestlé S.A. (CH) | 2018-06-14 | — | — | US | claimed |
| US-5665598-A | Synthesis of chiral N-protected-α-substituted-glycine free acids by zinc-mediated addition of organic halide to glycine cation equivalent | G. D. SEARLE & CO. (US) | 1997-09-09 | — | — | US | claimed |
| EP-0755379-A1 | SYNTHESIS N-PROTECTED AMINO ACIDS, ESPECIALLY N-BOC-L-PROPARGYLGLYCINE BY ZINC-MEDIATED ADDITION OR ORGANIC HALIDES TO GLYCINE CATION EQUIVALENT | G.D. SEARLE & CO. (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1995028385-A1 | SYNTHESIS N-PROTECTED AMINO ACIDS, ESPECIALLY N-BOC-L-PROPARGYLGLYCINE BY ZINC-MEDIATED ADDITION OR ORGANIC HALIDES TO GLYCINE CATION EQUIVALENT | G.D. SEARLE & CO. (US) | 1995-10-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | LIPC, GGT1, TGM2 | CA14 2395/4885KCNQ4 4600/4885KCNQ5 4749/4885 |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | LIPC, GGT1, TGM2 | CA14 2129/4885KCNQ4 4596/4885KCNQ5 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.